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Activation,  growth,  and  differentiation of B  lymphocytes is  controlled  by 
binding  of antigen  to  membrane  Ig  receptors,  by  interaction  with  antigen- 
specific, major histocompatibility antigen (MHC)-restricted helper T  cells,  and 
by the action of a series of soluble products derived from lymphocytes (lympho- 
kines) and  monocytes (monokines) (1-6).  Three responses  of B  cells  that are 
mediated by lymphokines are (a) induction of increased levels of class II MHC 
molecules (Ia antigens) on resting cells (7,  8), (b) stimulation of B cell entry into 
the S phase of the cell  cycle in  the presence  of low concentrations of anti-Ig 
antibodies (5,  9),  and (c)  expression and secretion of IgG1  in the presence of 
lipopolysaccharide (LPS) (10,  11). The former two responses are controlled by 
B cell stimulatory factor (BSF-1)  (previously, B cell growth factor or BCGF I), a 
protein with an Mr of 20,000 and pI of 6.3-6.6 and 7.4-7.6 (12,  13). BSF-1  has 
recently been purified to homogeneity (13)  and a  monoclonal anti-BSF-1  anti- 
body has  been  prepared  (14).  The  latter  response  is  due  to  the  action  of a 
lymphokine, termed  B  cell  differentiation factor for  IgG  (BCDF-~')  (10,  1 1), 
which has an M,. (10,  11) and pI (11,  12) similar to that of BSF-1.  In this report, 
we provide evidence that BCDF-7 and BSF-1 are the same lymphokine. 
Materials and Methods 
Purification of BSF-I.  BSF-1 was purified by reverse phase high performance liquid 
chromatography (HPLC) of serum-free supernatants (SN) from EL-4 cells (5, 13). HPLC- 
purified BSF-1 is enriched 2,500-fold and lacks interleukin  1 (IL-1), IL-2, IL-3, and ? 
interferon (IFN-?) activity (13). For some experiments,  HPLC-purified  BSF-1 was sepa- 
rated by preparative electrophoresis on sodium dodecyl sulfate-polyacrylamide gels (SDS- 
PAGE). BSF-1 was also purified by affinity chromatography of SN using a monoclonal 
anti-BSF-1 antibody (11B11) (14) conjugated  to Sepharose. The affinity-purified BSF-1 
was similar in purity to the material prepared by HPLC. 
Lymphokine Assays.  (a) BSF-1 activity was measured by its capacity to costimulate [3H]- 
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thymidine uptake by resting BALB/c or (C57BL/6 x  DBA/2)F] (BDF~) B cells (5) cultured 
with  either  a  soluble  monoclonal  rat  anti-mouse  IgM  antibody  (Bet2)  (15)  or  with 
Sepharose coupled to affinity-purified goat anti-mouse Ig (S-GAMIg) or goat anti-mouse 
6 (S-GAM-6) (16).  BSF-1  preparations  were added at the initiation  of culture and ['~H]- 
thymidine  (1  pCi/well)  was added  for the  last  16  h  of the  72  h  culture  period.  BSF-1 
activity was reported either as a stimulation index [3H]thymidine uptake in the presence 
of BSF-1/['~H]thymidine uptake in its absence) or in units (U), where  1 U  represents the 
amount of BSF-I required for half-maximal stimulation induced by a standard preparation 
of the BSF-l-containing EL-4 SN. 
(b)  BCDF-~F activity was measured by culturing T  cell-depleted  BDFI  spleen  cells in 
96-well Costar plates for 16 h in medium containing 20 #g/ml of LPS (10). Purified BSF- 
1  or  unfractionated  SN  were  added  after  16  h  and  the  cells  were  incubated  for  an 
additional  5  d.  On  the  6th  d,  the cell  SN were  harvested and assayed in a  solid phase 
radioimmunoassay (RIA) for the presence of secreted IgG1 and IgG3 (10). 
(c)  BCDF,p  activity was determined  using  the  in  vitro-adapted  clone of BCL~  cells 
(3B3) (17). Factors to be tested for BCDF-p activity were added at the initiation of the 6- 
d culture and the cells were incubated at 37°C in an atmosphere of 5% CO2. The cell SN 
were harvested and assayed by a solid phase RIA for the presence of secreted IgM (17). 
Results 
BCDF-"F Activity of Purified BSF-1.  Preparations of HPLC-purified BSF-1  and 
affinity-purified  BSF-1  were tested for their activity in the BSF-1, BCDF-~,, and 
BCDF-u assays.  2-10  U/ml  of BSF-1  in conjunction with S-GAMIg or S-GAM-6 
caused striking increases  in  [~H]thymidine  uptake and induction of lgG1  secre- 
tion  and  parallel  inhibition  of IgG3  secretion  in  LPS-stimulated  cells  (Fig.  1). 
The increases in IgG1  secretion and decreases in IgG3 secretion caused by BSF- 
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FIGURE  1.  BSF-1 purified by HPLC (to]))  or affinity chromatography on a monoclonal anti- 
BSF-1 Sepharose  colunm (bottom)  induced an increase in IgG1 secretion (a) and a decrease in 
IgG3 secretion  (b) in LPS-stimulated  murine B cells. It did not induce IgM secretion in BCL] 
cells (e). As a positive control, it caused an increase  in the BSF-l-mediated  incorporation of 
thymidine in S-GAMlg-stimulated  cells (d). Background values in the absence of BSF-I: lgM 
(BCDF-p), 34 +_ 6 ng/ml; IgGl (BCDF-~), 235 _+ 16 ng/ml; lgG3 (BCDF-3,), 1,800 ± 400 ng/ 
ml; [3H]thymidine (BSF-1), 2,458 + 350 cpm/105 cells. The stimulation  indices using optimal 
amounts of control PK 7.1  SN (2-5 #1) were:  BCDF-3, (lgGl, 94; IgG3, -40); BCDF-p, 5; 
BSF-l, 14. This is a representative experiment out of six for BCDF-3, (IgG 1), four for BCDF3' 
(IgG3), eight for BCDF-p, and five for BSF-1. 1728  VITETTA ET AL.  BRIEF  DEFINITIVE  REPORT 
1 preparation  were similar in magnitude to those obtained using the SN of the 
concanavalin A-pulsed, alloreactive T  cell clone PK 7.1 (18), the standard source 
of BCDF-'y (see Fig.  1 legend). It should be noted, however, that the majority of 
the cells producing IgG1  and  IgG3  are different (19).  Neither HPLC-purified 
BSF-1  nor affinity-purified BSF-1  bad any activity in the BCDF-/~ assay (Fig.  1), 
although the PK 7:1  SN was positive (see legend, Fig.  1). The effluent from the 
anti-BSF-1  affinity column was devoid of both BSF-1  and BCDF-"r activity but 
contained IL-2 and BCDF-# activity (data not shown). HPLC-purified BSF-1 was 
further purified  by SDS-PAGE.  Extracts  of eight  individual  bands,  migrating 
with apparent Mr of slightly more than 20,000 to 14,000, were tested for BSF-1 
and BCDF-3, activity. Fig. 2 illustrates a strong quantitative correlation between 
BSF-1 and BCDF-'y activities, with the three bands of Mr 20,000 having substan- 
tial activity in both assays. No BSF-1  or BCDF-3, activity was found in the lower 
molecular weight bands. 
Depletion of  BSF-1 and BCDF-~,  from T Cell Supernatants with a Monoclonal Anti- 
BSF-1 Antibody  Coupled  to Sepharose.  We next determined whether BSF-1  was 
the principal molecular species with BCDF-'y activity in the standard PK 7.1  SN 
(10). Since the IgGl-inducing factor produced by both PK 7.1  SN (10) and a  T 
cell hybridoma (11) has been reported to have an Mr of 20,000 and, in the case 
of the T  cell hybridoma (11), pIs similar to those of BSF-1 (12), we subjected SN 
from induced  PK  7.1  cells to affinity chromatograpby using Sepharose  conju- 
gated to  l 1B11.  As  shown in  Fig.  3,  the column removed BSF-I  and  BCDF-~, 
but not BCDF-~ activity from PK 7. I  SN. 
Ability of Monoclonal  Anti-BSF-1  to Block BCDF~[ Activity.  11BI 1 ascitic fluid, 
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FIC-URE 2.  BCDF-3,  (l~) and BSF-1 (Q) activity of HPLC-purified BSF-1 fractionated on 20% 
SDS-PAGE. The gel was stained with Coomassie Blue, and individual bands were cut from the 
geJ and  eluted  in  phosphate-buffered  saline containing 0.1% SDS. BCDF-2¢ activity was 
measured using 2 ~l of extract. BSF-1 activity was measured using dilutions of extract from 
l:l 0 to 1:100 and is reported in units. The background response in the BCDF-3, assay was 3 
_+ 0.4 ng/ml IgG. The experiment was repeated three times with similar results. V1TETTA  ET  AL.  BRIEF  DEFINITIVE  REPORT  1729 
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FIGURE  3.  The  monoclonal  anti-BSF-1  antibody  (11B11)  coupled  to  Sepharose  depleted 
BSF-1  and BCDF-~,  activity from PK 7.1  SN, but had no effect on BCDF-~ activity. Briefly, 
5.0 ml of PK  7.1  SN  were  passed over  1.0  ml of Sepharose anti-BSF-1.  The  material not 
adhering to the columns (0) was assayed for BCDF-% BCDF-u, and BSF-1 activities. In each 
case, the assay was compared with the PK 7.1 SN before passage over the affinity column (©). 
In the absence of PK 7.1  SN, the amount of IgM secreted in the BCDF-tt assay was 30 "4- 6 
ng/ml and the amount of IgG1  secreted  in the  BCDF-~,  assay was  255  +_.  18  ng/ml.  [SH]- 
thymidine incorporation per 105 cells was 3,424 _  186 cpm in the presence of S-GAM-& This 
is a  representative experiment out of three performed.  Similar results were obtained in the 
BSF-1 assay using S-GAMIg (two experiments). 
BSF  I   001 
-6  8O 
~  ao 
~  40 
20 
0  -  I 
-3  -4  -5  -6 
BCDFy  BCDFp 
I  I  l  I 
-3  -4  -5  -6  -3  -4.  -5  -6 
L-o9 Dilution  of  Ascites  ( IOFI ) 
F]CURE 4.  Monoclonal anti-BSF-1 blocks BSF-I and BCDF-',/activities, but not the BCDF-t~ 
activity of PK  7.1  SN.  10-tA dilutions of ascitic fluid containing monoclonal rat anti-BSF-I 
(11BI 1) or anti-DNP (50CI) antibody were added to cultures in which the BSF-I,  BCDF-% 
and BCDF-# activities of PK 7.1 SN were tested. The percent of the control response obtained 
with the  PK  7.1  SN  in  the presence of 50C1  ascites (0)  was compared with that using the 
11B11 ascites (O).  Neither ascites had any stimulatory or inhibitory effect in the assays when 
added  in  the absence of PK  7.1  SN  (data not  shown).  In  the absence of PK  7.1  SN,  the 
background values were  lgG1  (BCDF-7),  232  +-- 88  ng/ml; IgM  (BCDF-#I), 45  -+ 6  ng/ml; 
[SH]thymidine (BSF-1), 4,088 +  135 cpm/105 cells. This is a representative experiment out of 
four performed. 
prepared in nude mice, was tested for its ability to inhibit the activity of PK 7.1 
SN in the BSF-1  and BCDF-3'  assays.  Both functions were fully inhibited by 10 
#1 of a  1:1000  dilution of 11B11  ascitic fluid but not by a  control ascitic~fluid 
containing a  monoclonal anti-DNP  antibody (50C1)  (Fig.  4).  In  contrast,  the 
BCDF-# activity of PK 7.1  SN was not inhibited by 11B11  ascitic fluid. 
Discussion 
The observations that the induction of IgGl secretion and inhibition of IgG3 
secretion in  LPS-stimulated B cells are  functions of BSF-1 indicate a  need to 
reexamine the mechanism of action of this lymphokine. Recent evidence (7,  8) 1730  VITETTA  ET  AL.  BRIEF  DEFINITIVE  REPORT 
has  established  that  BSF-1  is  a  potent  activation  factor for resting  B  cells.  In 
contrast,  BSF-1  has  little or no capacity to sustain  proliferation of B  cell blasts 
after treatment with anti-Ig (9) or anti-~ plus BSF-1 (20). 
The present findings, taken together with results of past studies, suggest that 
BSF-1  is  a  pleiotropic activation  factor.  Thus,  it  appears  to  have  differential 
effects  on  resting  B  cells  and  on  a  subset  of LPS-stimulated  B  cells.  These 
divergent effects could result from different biochemical events initiated by the 
lymphokine. Alternatively, a  similar biochemical event induced by BSF-1  could 
lead to distinct pathways of gene activation or suppression  that depend on the 
state of differentiation of the target cell. To explore these alternatives, it will be 
important to determine whether BSF-1  regulates the expression of other classes 
of immunoglobulin  in  activated  B  cells  and  whether  the  biochemical  events 
induced by BSF-1  in resting and activated B cells are the same or different. 
Summary 
By three criteria, we have demonstrated that B cell stimulatory factor (BSF-1) 
and  B  cell  differentiation  factor  (BCDF-~')  are  the  same  lymphokine.  Highly 
purified preparations  of high  performance liquid  chromatography-purified or 
affinity-purified BSF-1  had BCDF-'~ activity but not BCDF-u activity. A  mono- 
clonal anti-BSF-1 antibody coupled to Sepharose depleted both BSF-1 and BCDF- 
3/activity but not BCDF-# activity from two different T  cell supernatants. Soluble 
monoclonal  anti-BSF-1  blocked  the  BSF-1  and  BCDF-3,  but  not  the  BCDF-~ 
responses. These results suggest that BSF-1 acts on both resting and activated B 
cells to induce different effects. 
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